Key facts
- OrisDX’s last known valuation is $14.0M (May 2025).
- It has raised $4.9M across 1 recorded rounds; the latest was Seed Round ($2.8M) in May 2025.
- Notable investors include Creative Destruction Lab, Polsky Center for Entrepreneurship and Innovation at the University of Chicago, MFV Partners, Angel Physicians Fund, CareQuest Innovation Partners — 8 tracked in total.
- OrisDX has filed 1 Form D with the SEC, most recently Jul 2025 ($2.8M sold to 25 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for OrisDX
Funding rounds
1 roundsAbout OrisDX
Developer of a novel non-invasive salivary diagnostic test designed to check oral cavity pre-malignancies and cancers. The company's product utilizes biomarker-based molecular genomic techniques to diagnose oral cavity cancers, enabling healthcare professionals to perform early diagnosis through non-invasive genetic testing of their saliva.
- Sector
- Healthcare
- HQ
- Chicago, IL, United States
- Founded
- 2022
- Employees
- 5
- Website
- orisdx.com/
- Ownership
- Privately Held (backing)
OrisDX doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in OrisDX shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on OrisDX in its N-PORT filings yet. We sweep new filings monthly.